CClinicalTrials.gg
Status unknownNCT03151850Updated May 12, 2017

The Diversity of the Fungal and Bacterial in Colon Mucosa of Patients With Different Degree of Inflammation of Ulcerative Colitis

An observational study in Ulcerative Colitis, sponsored by Xiuli Zuo. Status unknown at 1 site in China. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-12.

Sponsored by Xiuli Zuo · Observational

The sponsor has not verified this record recently (last verified May 2017), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years to 80 Years
Sex
All
01

Study summary

We analyzed the diversity of the fungal and bacterial within colon mucosa between patients with different degree of inflammation of Ulcerative Colitis.

Read the detailed description

In recent years, the relationship of intestinal fungus with inflammatory bowel disease was gradually revealed. We divided the patients with ulcerative colitis into three groups on the basis of World Gastroenterology Organisation (WGO) classification about inflammation degree and progress classification and established the healthy control group. Analyzing the diversity of the fungal and bacterial within colon mucosa between patients with different clinical classification, for example, the proportion of bacteria and fungi, the proportion of candida albicans, the proportion of yeasts, and so on.

02

Conditions studied

  • Ulcerative Colitis

Keywords

  • fungal
  • mucosa
  • diversity
  • Basidiomycete
03

In context

Colitis

1,073 studies on the registry are indexed under Colitis; 131 are open to participants now.

This study's planned enrollment of 50 is below the median of 105 across 247 observational studies indexed under Colitis.

Browse Colitis studies →

Lead sponsor

Xiuli Zuo is the lead sponsor of 10 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Consecutive patients under endoscopic surveillance or examination at Qilu Hospital were considered for inclusion.

Inclusion criteria

  • Patients at our tertiary care medical center, aged between 18 and 80 years, scheduled to undergo surveillance colonoscopy.
  • The patients with ulcerative colitis for ulcerative colitis group.
  • The patients without ulcerative colitis for control group.
  • 18-80 years.

Exclusion criteria

Exclusion Criteria:

  • Using antibiotics, glucocorticoid and immunosuppressants wintin one month.
  • There are contraindications for enteroscopy and biopsy.
  • There are other intestinal diseases.
  • Pregnancy or breast-feeding women.
  • Patients with serious lung disease and mental illness.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • ulcerative colitis

    We analysed the diversity of the fungal and bacterial in patients with Ulcerative Colitis (UC). We take 2 pieces of biopsies in the sigmoid colon mucosa inflammation area during the colonoscopy and then perform gene sequencing.

    Other: ulcerative colitis

  • Control

    Analysing the diversity of the fungal and bacterial in patients without ulcerative colitis. We take 2 pieces of biopsies in the sigmoid colon mucosa during the colonoscopy and then perform gene sequencing.

    Other: Control

Interventions

  • Otherulcerative colitis

    We take 2 pieces of biopsies in the sigmoid colon mucosa inflammation area during the colonoscopy and then perform gene sequencing.

    Also known as: Patients With ulcerative colitis

  • OtherControl

    We take 2 pieces of biopsies in the sigmoid colon mucosa during the colonoscopy and then perform gene sequencing.

    Also known as: Patients Without ulcerative colitis

06

What researchers measure

Primary outcomes

  1. fungus detection rate

    Fungi detection rate was defined as the percentage of patients in whose colonic mucosa at least one kind of fungus were identified.

    Time frame: 6 months

  2. yeasts detection rate

    Yeasts detection rate was defined as the percentage of patients in whose colonic mucosa yeasts were identified.

    Time frame: 6 months

  3. candida albicans detection rate

    Candida albicans detection rate was defined as the percentage of patients in whose colonic mucosa candida albicans were identified.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Qilu Hospital, Shandong University
    Jinan, Shandong 250012, China
    • Xiuli Zuo, PhD · Contact · zuoxiuli@sina.com · 15588818685
    • Lidong Xu, MD · Sub investigator
    Recruiting
08

References and documents

Publications

  • Sokol H, Leducq V, Aschard H, Pham HP, Jegou S, Landman C, Cohen D, Liguori G, Bourrier A, Nion-Larmurier I, Cosnes J, Seksik P, Langella P, Skurnik D, Richard ML, Beaugerie L. Fungal microbiota dysbiosis in IBD. Gut. 2017 Jun;66(6):1039-1048. doi: 10.1136/gutjnl-2015-310746. Epub 2016 Feb 3. PubMed 26843508 ↗
  • Mukhopadhya I, Hansen R, Meharg C, Thomson JM, Russell RK, Berry SH, El-Omar EM, Hold GL. The fungal microbiota of de-novo paediatric inflammatory bowel disease. Microbes Infect. 2015 Apr;17(4):304-10. doi: 10.1016/j.micinf.2014.12.001. Epub 2014 Dec 15. PubMed 25522934 ↗
  • Eriksson M, Johannssen T, von Smolinski D, Gruber AD, Seeberger PH, Lepenies B. The C-Type Lectin Receptor SIGNR3 Binds to Fungi Present in Commensal Microbiota and Influences Immune Regulation in Experimental Colitis. Front Immunol. 2013 Jul 16;4:196. doi: 10.3389/fimmu.2013.00196. eCollection 2013. PubMed 23882266 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03151850
Lead sponsor
Xiuli Zuo
Collaborators
Qilu Hospital of Shandong University
Responsible party
Xiuli Zuo (Deputy director of the physician, Shandong University) — Sponsor-investigator
First posted
May 12, 2017
Start date
Jul 2016
Primary completion
Aug 2017 (estimated)
Completion
Aug 2017 (estimated)
Last update
May 12, 2017

Study contacts

Xiuli Zuo, PhD
Contact
zuoxiuli@sina.com
15588818685 ext. 053188369277
Xiuli Zuo, PhD
principal investigator · Qilu Hospital of Shandong University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion